In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. Advances also included December approvals, promising ADC research in NSCLC, and potential future FDA approvals under consideration.
The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
This cohort study examines whether there is an association of diet quality and dietary inflammatory potential with prostate cancer grade reclassification in men with grade…
The negative patient-reported effects associated with a CSD result from MCED testing were small and returned to baseline within 12 months for participants with or…
PURPOSEIn patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
During the Multiple Myeloma Hub Steering Committee Meeting in November 2024, key opinion leaders met to discuss belantamab mafodotin combination therapies in early RRMM, with…
Jeffrey Matous, MD, Colorado Blood Cancer Institute, Denver, CO, comments on the potential benefits of using alternative teclistamab step-up dosing strategies in patients with relapsed/refractory…
A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified…
